enGene Therapeutics (ENGN) Change in Account Payables (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Change in Account Payables of -$625000.0 for Q2 2026, up 35.83% year-over-year from -$460128.5 in Q2 2025, and up 85.36% quarter-over-quarter from -$4.3 million in Q1 2026.
enGene Therapeutics (ENGN) Change in Account Payables (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Change in Account Payables for 4 consecutive years, with -$625000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables rose 35.83% year-over-year to -$625000.0; the TTM figure through Apr 2026 stood at -$105000.0 (down 107.98% YoY), while the FY2025 annual figure was $4.9 million, up 942.62% from the prior year.
- Change in Account Payables climbed to -$625000.0 in Q2 2026 per ENGN's latest filing, from -$4.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.0 million in Q4 2025 and bottomed at -$4.3 million in Q1 2026.
- Historically, Change in Account Payables has averaged $63857.1 across 4 years, with a median of -$189000.0 in 2023.
- Annual changes were most pronounced in 2025 — Change in Account Payables surged 418.89% — and 2026, when it plunged 479.22%.
- enGene Therapeutics' Change in Account Payables stood at -$595000.0 in 2023, then sank by 142.86% to -$1.4 million in 2024, then jumped by 374.88% to $4.0 million in 2025, then sank by 115.74% to -$625000.0 in 2026.
- Business Quant data shows ENGN's Change in Account Payables at -$625000.0 in Q2 2026, -$4.3 million in Q1 2026, and $4.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -625,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -625,000.00 |
| Apr 30, 2026 | -625,000.00 |
| Jan 31, 2026 | -4.27 Mn |
| Jan 31, 2026 | -4.27 Mn |
| Oct 31, 2025 | 3.97 Mn |
| Oct 31, 2025 | 3.97 Mn |
| Jul 31, 2025 | 818,000.00 |
| Jul 31, 2025 | 818,000.00 |
| Apr 30, 2025 | -974,000.00 |
| Apr 30, 2025 | -974,000.00 |
| Jan 31, 2025 | 1.13 Mn |
| Jan 31, 2025 | 1.13 Mn |
| Oct 31, 2024 | -1.45 Mn |
| Oct 31, 2024 | -1.45 Mn |
| Jul 31, 2024 | 2.61 Mn |
| Jul 31, 2024 | 2.61 Mn |
| Apr 30, 2024 | -906,000.00 |
| Apr 30, 2024 | -906,000.00 |
| Jan 31, 2024 | 217,000.00 |
| Jan 31, 2024 | 217,000.00 |